Group 1 - Yong'an Pharmaceutical announced that its stock price has significantly increased recently, leading to a high risk of speculation, although there are no major changes in the company's fundamentals [3] - *ST Tongzhou will lift the delisting risk warning and other risk warnings starting June 17, with the stock name changing from "*ST Tongzhou" to "Tongzhou Electronics" and the daily price fluctuation limit changing to 10% [4] - Guangsheng Pharmaceutical's subsidiary received ethical review approval for a Phase III clinical trial of its innovative hepatitis B treatment, GST-HG141, which will be led by a prominent researcher [5] - Huahai Pharmaceutical received a drug registration certificate for its sustained-release formulation of fumaric acid quetiapine, aimed at treating schizophrenia and bipolar disorder [6] - Bozhong Precision plans to acquire 70% of Shanghai Wodian for 420 million yuan, aiming to enter the automotive intelligent equipment market [7] Group 2 - Baoli International's shareholder plans to reduce his stake by up to 3%, equating to a maximum of 27.468 million shares [9] - Guomao Co., Ltd.'s actual controllers intend to collectively reduce their holdings by up to 3%, totaling a maximum of 19.7726 million shares [10] - Heng Rui Pharmaceutical's director plans to reduce his holdings by up to 47,670 shares, representing 0.007% of the total share capital [11] - Shandong Zhanggu's directors and executives plan to collectively reduce their holdings by up to 155,080 shares, accounting for 0.5% of the total share capital [12] - Den Precision's executives plan to reduce their holdings by up to 29,550 shares, which is 0.2% of the total share capital [13] - Lian Technology's supervisory board chairman plans to reduce his holdings by up to 7,500 shares, representing 0.013% of the total share capital [14] - Guomai Culture's vice president plans to reduce his holdings by up to 5,050 shares, which is 0.05% of the total share capital [15] - Xiangfenghua's general manager plans to reduce his holdings by up to 25,000 shares, equating to 0.02% of the total share capital [16] Group 3 - Jintian International announced it won a bid for the intelligent upgrade project of the warehouse for China General Nuclear Power Group, with a contract value of 22 million yuan, representing 0.93% of the company's projected revenue for 2024 [18]

Core Viewpoint - Huahai Pharmaceutical (600521.SH) has received approval from the National Medical Products Administration for the registration of Fumaric Acid Quetiapine Extended-Release Tablets, which are used to treat schizophrenia and depressive episodes of bipolar disorder [1] Summary by Relevant Categories Product Approval - The approved drug was originally developed by AstraZeneca and was launched in the United States in 2007 [1] - The approval of this drug enhances the company's product line and improves its market competitiveness [1] Market Potential - According to data from Minet, the projected domestic market sales for this drug are approximately 451 million yuan in 2024 [1] R&D Investment - The company has invested approximately 16.93 million yuan in the research and development of this project [1]

Core Insights - The company announced that its wholly-owned subsidiary, China National Pharmaceutical Group Industrial Co., Ltd., and its controlling subsidiary, China National Pharmaceutical Yixin Pharmaceutical Co., Ltd., have obtained drug registration certificates for two medications: Fumaric Acid Quetiapine Sustained-Release Tablets and Capecitabine Tablets [1] Group 1: Drug Registration and Sales - Fumaric Acid Quetiapine Sustained-Release Tablets are primarily used for the treatment of schizophrenia and bipolar disorder, with sales in public hospitals and urban pharmacies reaching 445 million yuan in 2023 [1] - Capecitabine Tablets are indicated for metastatic colorectal cancer, achieving sales of 164 million yuan in public hospitals and urban pharmacies in 2023 [1] Group 2: R&D Investment - China National Pharmaceutical Group Industrial Co., Ltd. and China National Pharmaceutical Yixin Pharmaceutical Co., Ltd. have made cumulative R&D investments of approximately 16.32 million yuan and 27.50 million yuan, respectively [1]